A prescription medicine used to lower levels of bad cholesterol (LDL-C) in the blood. It contains alirocumab, a monoclonal antibody that helps the liver remove LDL-C from the bloodstream.

Indications:
- Treatment of adults with cardiovascular disease to reduce the risk of heart attack, stroke, and certain types of chest pain (unstable angina) requiring hospitalization, along with diet, alone or together with other cholesterol-lowering medicines.
- Treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) as an adjunct to diet and other LDL-C lowering therapies.
- Reduction of LDL-C in adults with homozygous familial hypercholesterolemia.
- Treatment of children aged 8 years and older with heterozygous familial hypercholesterolemia.

Main Active Ingredients:
- Alirocumab 75 mg per 1 mL pre-filled pen.

Precautions:
- For subcutaneous use only.
- Use with caution in patients with liver or kidney impairment.
- Not recommended for children under 8 years of age.
- Discontinue immediately if signs of hypersensitivity occur.
- Consult a doctor before use during pregnancy or breastfeeding.
- Store in a refrigerator (2–8 °C). Do not freeze. May be kept at room temperature (up to 25 °C) for a maximum of 30 days in the original carton to protect from light.

Side Effects:
- Pain, redness, or swelling at the injection site.
- Nasopharyngitis.
- Flu-like symptoms.
- Muscle pain.
- Allergic skin reactions such as rash or urticaria.

Drug-Drug Interactions:
- No known pharmacokinetic interactions due to monoclonal antibody structure.
- Monitor when used with other lipid-lowering medications.
- Inform your healthcare provider about all medicines, supplements, or herbal products taken concurrently.